PHASE II PLACEBO-CONTROLLED STUDY OF VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA VACCINE) DELIVERED IM FOLLOWED BY ELECTROPORATION (EP) WITH CELLECTRA -5P FOR THE TREATMENT OF BIOPSY-PROVEN CIN 2/3 OR CIN 3 WITH DOCUMENTED HPV 16 OR 18

Trial Profile

PHASE II PLACEBO-CONTROLLED STUDY OF VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA VACCINE) DELIVERED IM FOLLOWED BY ELECTROPORATION (EP) WITH CELLECTRA -5P FOR THE TREATMENT OF BIOPSY-PROVEN CIN 2/3 OR CIN 3 WITH DOCUMENTED HPV 16 OR 18

Completed
Phase of Trial: Phase II

Latest Information Update: 05 May 2016

At a glance

  • Drugs VGX 3100 (Primary)
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Therapeutic Use
  • Sponsors Inovio Pharmaceuticals
  • Most Recent Events

    • 05 May 2016 According to an Inovio Pharmaceuticals media release, data from this trial will be presented at the 19th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) 2016.
    • 22 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Sep 2015 Results published in the Internet Document.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top